H.C. Wainwright & Co. Managing Director of Equity Research and Senior Healthcare Analyst Raghuram Selvaraju, Ph.D. just reiterated his ‘Buy’ rating on shares of Intec Pharma Ltd. (NASDAQ:NTEC) alongside a price target of $16 USD per share.
Analyst Raghuram Selvaraju commented, “We utilize a discounted cash flow-based risk- adjusted net present value (rNPV) approach in assessing Intec, which deploys a 12% discount rate and 85% probability of success to yield a projected value of $430M. This translates into a price per share of $16.00, assuming roughly 33M shares outstanding as of end-2Q19.”
Based on a last-traded price of $5.50 USD for shares of NTEC on the NASDAQ, Raghuram Selvaraju’s price target represents approximately 190% of potential upside.
We’ll continue to monitor analyst activity and in the meantime, be sure to subscribe to Cannabis Biotech Updates here and Cannabis Stock Updates here so you never miss an important update. For Intec-specific updates, be sure to subscribe to Intec Pharma Updates here.
Get Real-Time Updates from MJobserver.com
